PFE
| Market cap | $291.64B |
|---|---|
| Enterprise value | $219.45B |
| Revenue | $55.094B |
|---|---|
| EBITDA | $7.419B |
| Income | -$309.00 |
| Revenue Q/Q | -18.61% |
| Revenue Y/Y | -40.73% |
| P/E | N/A |
|---|---|
| Forward P/E | 7.58 |
| EV/Sales | 3.98 |
| EV/EBITDA | 29.58 |
| EV/EBIT | N/A |
| PEG | 1.17 |
| Price/Sales | 5.29 |
| P/FCF | 57.12 |
| Price/Book | 3.28 |
| Book/Share | 8.37 |
| Cash/Share | 1.19 |
| FCF yield | 1.75% |
| Volume | 29.528M / 28.251M |
|---|---|
| Relative vol. | 1.05 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | 1,968.22% |
| Est. EPS Q/Q | 28.05% |
| Profit margin | 3.62% |
|---|---|
| Oper. margin | -3.25% |
| Gross margin | 57.34% |
| EBIT margin | -3.35% |
| EBITDA margin | 13.47% |
| Ret. on assets | -0.14% |
|---|---|
| Ret. on equity | -0.33% |
| ROIC | 0.48% |
| ROCE | -1.02% |
| Debt/Equity | 1.54 |
|---|---|
| Net debt/EBITDA | 21.13 |
| Current ratio | 1.05 |
| Quick ratio | 0.78 |
| Volatility | 2.26% |
|---|---|
| Beta | 0.40 |
| RSI | 42.96 |
|---|
| Insider ownership | 0.04% |
|---|---|
| Inst. ownership | 69.08% |
| Shares outst. | 5.667B |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 1.11% |
| Short ratio | 3.19 |
| Dividend | $1.66 |
|---|---|
| Dividend yield | 6.15% |
| Payout ratio | 434.21% |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 30 Jul 2024 |
Monday, 17 June 2024
|
|
| Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit | |
Thursday, 13 June 2024
|
|
| Redditors Are Buying These 8 Dividend Stocks For Early Retirement | |
| Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test | |
Wednesday, 12 June 2024
|
|
| Pfizer: An Oversold Pharma Stock in Recovery | |
Friday, 31 May 2024
|
|
| The Most Profitable Biotechnology Company in the World | |
| How To Earn $500 A Month From Pfizer Stock | |
Wednesday, 22 May 2024
|
|
| Pfizer targets $1.5 billion in savings by 2027 as it streamlines operations | |
Tuesday, 21 May 2024
|
|
| GSK's New Vaccine Kept the Boss in Her Job — and an Activist at Bay | |
Monday, 20 May 2024
|
|
| Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute | |
Friday, 17 May 2024
|
|
| Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech | |
Thursday, 16 May 2024
|
|
| Pfizer offers up to $250 million to settle Zantac cancer lawsuits, FT reports | |
Monday, 13 May 2024
|
|
| Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients | |
Friday, 10 May 2024
|
|
| A Struggling Pfizer Looks for Help From a Wall Streeter | |
| Decoding Pfizer Inc : A Strategic SWOT Insight | |
Wednesday, 8 May 2024
|
|
| UPDATE 1-Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports | |
| Pfizer Inc's Dividend Analysis | |
Tuesday, 7 May 2024
|
|
| UPDATE 1-Pfizer reports patient death in Duchenne gene therapy study | |
| Pfizer reports patient death in Duchenne gene therapy study | |
| 15 Best S&P 500 Dividend Stocks To Buy Now | |
Monday, 6 May 2024
|
|
| Pfizer Is Adding a Wall Street Analyst to Its C-Suite. What He Thinks the Company Needs to Do. | |
| BioNTech says 90% of 2024 revenues will accrue at end of year | |
Thursday, 2 May 2024
|
|
| Why Markets Must Beware Powell’s Comments on Fed Rate Hikes, and 5 Other Things to Know Today | |
Wednesday, 1 May 2024
|
|
| Pfizer lifts 2024 profit view on cost cuts, higher COVID vaccine demand | |
Monday, 29 April 2024
|
|
| UPDATE 1-US FDA grants full approval for Pfizer's cervical cancer drug | |
| mRNA Is Promising A Breakthrough In Fighting Cancer | |
Friday, 26 April 2024
|
|
| A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed | |
| FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia | |
Tuesday, 23 April 2024
|
|
| Pfizer vs Moderna battle over COVID vaccine patents begins in UK | |
Sunday, 21 April 2024
|
|
| 11 Best Low Price Pharma Stocks To Invest In | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Michael Mc Dermott Executive Vice President | Option 23 Feb 2024 | $339,344 |
| Sally Susman Executive Vice President | Option 23 Feb 2024 | $1,745,304 |
| Payal Sahni Executive Vice President | Option 23 Feb 2024 | $315,148 |
| Douglas M Lankler Executive Vice President | Option 23 Feb 2024 | $2,617,942 |
| Rady A Johnson Executive Vice President | Option 23 Feb 2024 | $804,780 |
| Jennifer B. Damico SVP and Controller | Option 23 Feb 2024 | $266,620 |
| Albert Bourla Chairman and CEO | Option 23 Feb 2024 | $3,490,607 |
| Christoffel Boshoff Executive Vice President | Option 23 Feb 2024 | $266,620 |
| Scott Gottlieb Director | Buy 15 Dec 2023 | $79,410 |
| Scott Gottlieb Director | Buy 5 May 2023 | $77,000 |
| Payal Sahni Executive Vice President | Option 25 Feb 2023 | $204,202 |
Powered by
Robintrack.
Price target
Current $27.53
Average $40.44
Low $34
High $53
Dividends
| Ex-dividend date | N/A | Frequency | Quarterly | Annual dividend | +2.50% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 6.15% | Growth period | 13 years |
| Last dividend date | Yield 3 years | 4.99% | Growth 3 years | +2.57% | |
| Last dividend | Yield 5 years | 4.35% | Growth 5 years | +3.82% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Albert Bourla (58) Chairman of the Board and Chief Executive Officer since 2020 | 58 | 2020 | $17,929,000 |
| Frank D'Amelio (62) Chief Financial Officer, Executive Vice President - Business Operations, and Global Supply since 2018 | 62 | 2018 | $11,075,700 |
| Mikael Dolsten (61) Chief Scientific Officer, President - Worldwide Research, Development, and Medical since 2019 | 61 | 2019 | $9,598,040 |
| John Young (55) Chief Business Officer and Group President since 2019 | 55 | 2019 | $8,959,380 |
| Dr. Albert Bourla D.V.M., DVM, Ph.D. (59) Chairman and CEO | 59 | $7,985,022 | |
| Frank A. D'Amelio (63) CFO and Exec. VP | 63 | $5,143,250 | |
| Dr. Mikael Dolsten M.D., Ph.D. (63) Chief Scientific Officer, Pres of Worldwide Research, Devel., and Medical | 63 | $4,501,569 | |
| Angela Hwang (55) Group Pres of Biopharmaceuticals Group | 55 | $3,971,014 | |
| John D. Young (56) Advisor | 56 | $3,535,994 | |
| Shantanu Narayen (56) Lead Independent Director since 2019 | 56 | 2019 | $400,000 |
| Wyllie Don Cornwell (72) Independent Director since 1997 | 72 | 1997 | $385,000 |
| Helen Hobbs | 2011 | $383,600 | |
| Suzanne Nora Johnson (62) Independent Director since 2007 | 62 | 2007 | $380,000 |
| Joseph Echevarria (63) Independent Director since 2015 | 63 | 2015 | $365,000 |
| James Kilts | 2007 | $355,000 | |
| Ronald Blaylock (60) Independent Director since 2017 | 60 | 2017 | $350,000 |
| Dan Littman (67) Independent Director since 2018 | 67 | 2018 | $344,700 |
| Scott Gottlieb (47) Independent Director since 2019 | 47 | 2019 | $231,621 |
| James Quincey (55) Independent Director since 2020 | 55 | 2020 | |
| Susan Hockfield (69) Independent Director since 2020 | 69 | 2020 | |
| Susan Desmond-Hellmann (62) Director since 2020 | 62 | 2020 | |
| Gordon Loh | 2020 | ||
| Jennifer Damico (52) Senior Vice President, Principal Accounting Officer, and Controller since 2020 | 52 | 2020 | |
| Sally Susman (58) Chief Corporate Affairs Officer and Executive Vice President since 2019 | 58 | 2019 | |
| Alexander Mackenzie (60) Executive Vice President and Chief Development Officer since 2016 | 60 | 2016 | |
| Douglas Lankler (54) Executive Vice President and General Counsel since 2014 | 54 | 2014 | |
| Rady Johnson (58) Chief Compliance, Quality, Risk Officer, and Executive Vice President since 2019 | 58 | 2019 | |
| Lidia Fonseca (51) Executive Vice President, Chief Technology Officer, and Digital Officer since 2019 | 51 | 2019 | |
| Dawn Rogers (55) Chief Human Resource Officer and Executive Vice President since 2019 | 55 | 2019 | |
| Angela Hwang (54) Group President and Pfizer Biopharmaceuticals Group since 2019 | 54 | 2019 | |
| Rady A. Johnson (59) Exec. VP, Chief Compliance, Quality, and Risk Officer | 59 | ||
| Douglas M. Lankler (55) Exec. VP and Gen. Counsel | 55 | ||
| Christopher J. Stevo CFA | |||
| Lidia L. Fonseca (52) Exec. VP, Chief Digital, and Technology Officer | 52 | ||
| Jennifer B. Damico (53) Sr. VP, Controller, and Principal Accounting Officer | 53 | ||
| Mike McDermott |
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
- Health Care > Pharmaceuticals
- Pfizer Inc., 235 East 42nd Street, New York 10017, United States
- 212 733 2323
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Quarterly | Annual dividend | +2.50% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 6.15% | Growth period | 13 years |
| Last dividend date | Yield 3 years | 4.99% | Growth 3 years | +2.57% | |
| Last dividend | Yield 5 years | 4.35% | Growth 5 years | +3.82% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $719 | $2,853 | |||
| Short term investments | $11,209 | $9,837 | |||
| Net receivables | $10,989 | $11,177 | |||
| Inventory | $10,892 | $10,189 | |||
| Total current assets | $42,415 | $43,333 | |||
| Long term investments | $11,613 | $15,368 | |||
| Property, plant & equipment | $18,803 | $18,940 | |||
| Goodwill & intangible assets | $132,126 | $132,683 | |||
| Total noncurrent assets | $178,680 | $183,168 | |||
| Total investments | $22,822 | $25,205 | |||
| Total assets | $221,095 | $226,501 | |||
| Current liabilities | |||||
| Accounts payable | $5,591 | $6,710 | |||
| Deferred revenue | $2,502 | $2,700 | |||
| Short long term debt | $8,232 | $10,350 | |||
| Total current liabilities | $40,497 | $47,794 | |||
| Long term debt | $61,307 | $61,538 | |||
| Total noncurrent liabilities | $88,040 | $89,419 | |||
| Total debt | $69,539 | $71,888 | |||
| Total liabilities | $128,537 | $137,213 | |||
| Stockholders' equity | |||||
| Retained earnings | $121,318 | $118,353 | |||
| Other stockholder equity | -$7,758 | -$7,961 | |||
| Total stockholder equity | $92,282 | $89,014 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2,853 | $416 | ||
| Short term investments | $9,837 | $22,316 | ||
| Net receivables | $11,177 | $10,952 | ||
| Inventory | $10,189 | $8,981 | ||
| Total current assets | $43,333 | $51,259 | ||
| Long term investments | $15,368 | $15,069 | ||
| Property, plant & equipment | $18,940 | $16,274 | ||
| Goodwill & intangible assets | $132,683 | $94,745 | ||
| Total noncurrent assets | $183,168 | $145,946 | ||
| Total investments | $25,205 | $37,385 | ||
| Total assets | $226,501 | $197,205 | ||
| Current liabilities | ||||
| Accounts payable | $6,710 | $6,809 | ||
| Deferred revenue | $2,700 | $2,520 | ||
| Short long term debt | $10,350 | $2,945 | ||
| Total current liabilities | $47,794 | $42,138 | ||
| Long term debt | $61,538 | $32,884 | ||
| Total noncurrent liabilities | $89,419 | $59,150 | ||
| Total debt | $71,888 | $35,829 | ||
| Total liabilities | $137,213 | $101,288 | ||
| Stockholders' equity | ||||
| Retained earnings | $118,353 | $125,656 | ||
| Other stockholder equity | -$7,961 | -$8,304 | ||
| Total stockholder equity | $89,014 | $95,661 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $14,879 | $14,249 | |||
| Cost of revenue | $3,379 | $7,563 | |||
| Gross profit | $11,500 | $6,686 | |||
| Operating activities | |||||
| Research & development | $2,493 | $2,815 | |||
| Selling, general & administrative | $3,495 | $4,575 | |||
| Total operating expenses | $8,078 | $10,816 | |||
| Operating income | $3,422 | -$4,130 | |||
| Income from continuing operations | |||||
| EBIT | $3,408 | -$4,164 | |||
| Income tax expense | $293 | -$795 | |||
| Interest expense | |||||
| Net income | |||||
| Net income | $3,115 | -$3,369 | |||
| Income (for common shares) | $3,115 | -$3,369 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $58,496 | $100,330 | ||
| Cost of revenue | $24,954 | $34,344 | ||
| Gross profit | $33,542 | $65,986 | ||
| Operating activities | ||||
| Research & development | $10,679 | $11,428 | ||
| Selling, general & administrative | $14,771 | $13,677 | ||
| Total operating expenses | $32,485 | $31,259 | ||
| Operating income | $1,057 | $34,727 | ||
| Income from continuing operations | ||||
| EBIT | $1,004 | $34,700 | ||
| Income tax expense | -$1,115 | $3,328 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | $2,119 | $31,372 | ||
| Income (for common shares) | $2,119 | $31,372 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | $3,115 | -$3,369 | |||
| Operating activities | |||||
| Depreciation | $1,736 | $1,670 | |||
| Business acquisitions & disposals | $3,491 | -$43,405 | |||
| Stock-based compensation | $220 | $121 | |||
| Total cash flows from operations | $1,090 | $5,240 | |||
| Investing activities | |||||
| Capital expenditures | -$704 | -$1,044 | |||
| Investments | -$1,056 | $33,438 | |||
| Total cash flows from investing | $1,732 | -$10,996 | |||
| Financing activities | |||||
| Dividends paid | -$2,372 | -$2,315 | |||
| Sale and purchase of stock | |||||
| Net borrowings | -$2,173 | $7,775 | |||
| Total cash flows from financing | -$4,931 | $5,442 | |||
| Effect of exchange rate | -$28 | -$1 | |||
| Change in cash and equivalents | -$2,137 | -$316 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | $2,119 | $31,372 | ||
| Operating activities | ||||
| Depreciation | $6,290 | $5,064 | ||
| Business acquisitions & disposals | -$43,430 | -$19,037 | ||
| Stock-based compensation | $525 | $872 | ||
| Total cash flows from operations | $8,700 | $29,267 | ||
| Investing activities | ||||
| Capital expenditures | -$3,907 | -$3,236 | ||
| Investments | $15,239 | $6,682 | ||
| Total cash flows from investing | -$32,278 | -$15,783 | ||
| Financing activities | ||||
| Dividends paid | -$9,247 | -$8,983 | ||
| Sale and purchase of stock | -$2,000 | |||
| Net borrowings | $35,945 | -$3,516 | ||
| Total cash flows from financing | $26,066 | -$14,834 | ||
| Effect of exchange rate | -$40 | -$165 | ||
| Change in cash and equivalents | $2,448 | -$1,515 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Wellington Management Group LL.P. |
-25.71%
|
177,697,620 | $4,931,108,957 |
| 2024 Q1 | Capital World Investors |
-35.03%
|
112,661,481 | $3,126,356,099 |
| 2024 Q1 | Two Sigma Advisers, L.P. |
+348.17%
|
13,547,300 | $375,937,575 |
| 2024 Q1 | Barclays PLC |
+85.50%
|
21,565,306 | $598,437 |
| 2024 Q1 | Two Sigma Investments, L.P. |
Opened
|
8,419,014 | $233,627,639 |
| 2024 Q1 | D1 Capital Partners L.P. |
Opened
|
7,830,000 | $217,282,500 |
| 2024 Q1 | Amundi |
+20.29%
|
46,355,842 | $1,188,222,291 |
| 2024 Q1 | Caisse De Depot Et Placement Du Quebec |
-38.83%
|
11,433,418 | $317,277,357 |
| 2024 Q1 | Clearbridge Investments |
-91.82%
|
632,960 | $17,564,634 |
| 2024 Q1 | Dimensional Fund Advisors L.P. |
-14.97%
|
35,689,840 | $990,393,050 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Metatron Capital Sicav PLC | 99.05% | 5,612,866,598 | |
| Vanguard Group Inc | 8.94% | 506,727,929 | |
| Blackrock | 7.61% | 431,118,406 | |
| State Street Corp | 5.13% | 290,696,984 | |
| Wellington Management Group LL.P. | 3.14% | 177,697,620 | |
| Capital World Investors | 1.99% | 112,661,481 | |
| Geode Capital Management | 1.93% | 109,534,217 | |
| Charles Schwab Investment Management Inc | 1.84% | 104,246,432 | |
| Morgan Stanley | 1.50% | 84,792,839 | |
| Norges Bank | 1.31% | 73,981,480 |
Sign up